COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Prognostic Factors Affecting Duchenne Muscular Dystrophy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03372655
Recruitment Status : Unknown
Verified December 2017 by Nehal Refaat Mohammed, Assiut University.
Recruitment status was:  Not yet recruiting
First Posted : December 14, 2017
Last Update Posted : December 14, 2017
Information provided by (Responsible Party):
Nehal Refaat Mohammed, Assiut University

Brief Summary:
Determination of prognostic factors affecting ambulation of duchenne muscular dystrophy

Condition or disease
Duchenne Muscular Dystrophy

Detailed Description:
Duchenne muscular dystrophy is the most common herditary muscular disease , it lead to loss of ambulation in early teenageers . It lead to early death at the mean age of 19 years

Layout table for study information
Study Type : Observational
Estimated Enrollment : 82 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prognstic Factors Affecting Duchenne Muscular Dystrophy
Estimated Study Start Date : January 1, 2018
Estimated Primary Completion Date : January 1, 2019
Estimated Study Completion Date : March 1, 2019

Primary Outcome Measures :
  1. Ten meter walking test [ Time Frame: 2018 - 2019 ]

Secondary Outcome Measures :
  1. Muscle strenght [ Time Frame: 2018- 2019 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   10 Years to 18 Years   (Child, Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Male patient diagnosed as duchenne muscular dystrophy by typical clinical picture&shooting serum CPK level & EMG study or biopsy

Inclusion Criteria:

  • any male pt diagnosed as duchenne muscular dystrophy by typical clinical picture &shooting serum CPK level &EMG study or biopsy & age 10 to 18yrs old

Exclusion Criteria:

  • female patient ' age below 10 yrs old or above 18 yrs old .patient with autoimmune disease or malignancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03372655

Layout table for location contacts
Contact: Nehal Refaat, Residant 01000242438

Sponsors and Collaborators
Assiut University
Layout table for additonal information
Responsible Party: Nehal Refaat Mohammed, Sponsor investigator, Assiut University Identifier: NCT03372655    
Other Study ID Numbers: PFADMD
First Posted: December 14, 2017    Key Record Dates
Last Update Posted: December 14, 2017
Last Verified: December 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked